Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity
暂无分享,去创建一个
A. Nagler | R. Yerushalmi | A. Shimoni | A. Shimoni | Y. Volchek | N. Shem-Tov | I. Danylesko | Arnon Nagler
暂无分享,去创建一个
A. Nagler | R. Yerushalmi | A. Shimoni | A. Shimoni | Y. Volchek | N. Shem-Tov | I. Danylesko | Arnon Nagler